<div id="readability-page-1"><p>Riverbend Wealth Management LLC bought a new position in  Medtronic plc (NYSE:MDT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The firm bought 2,955 shares of the medical technology company's stock, valued at approximately $237,000.</p><ul><li>MarketBeat Week in Review – 02/17 - 02/21</li></ul><p>Several other institutional investors and hedge funds have also made changes to their positions in MDT. Copley Financial Group Inc. purchased a new stake in  Medtronic in the 3rd quarter valued at about $694,000.  Franklin Street Advisors Inc. NC boosted its holdings in shares of  Medtronic by 32.6% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 73,517 shares of the medical technology company's stock valued at $5,873,000 after purchasing an additional 18,057 shares during the period.  Y Intercept Hong Kong Ltd grew its stake in  Medtronic by 322.6% in the third quarter. Y Intercept Hong Kong Ltd now owns 73,593 shares of the medical technology company's stock worth $6,626,000 after purchasing an additional 56,178 shares in the last quarter.  Olstein Capital Management L.P. increased its holdings in  Medtronic by 8.0% during the 4th quarter. Olstein Capital Management L.P. now owns 94,000 shares of the medical technology company's stock worth $7,509,000 after purchasing an additional 7,000 shares during the period.  Finally, Czech National Bank raised its position in  Medtronic by 6.4% during the 4th quarter. Czech National Bank now owns 278,065 shares of the medical technology company's stock valued at $22,212,000 after purchasing an additional 16,786 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors. </p><h2>Medtronic Price Performance</h2><p>Shares of NYSE MDT opened at $93.75 on Tuesday. Medtronic plc has a fifty-two week low of $75.96 and a fifty-two week high of $96.25. The company has a market cap of $120.24 billion, a PE ratio of 28.50, a P/E/G ratio of 2.22 and a beta of 0.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.39 and a current ratio of 1.90. The business has a 50-day simple moving average of $88.62 and a two-hundred day simple moving average of $87.84. </p><ul><li>Medtronic’s Expansion Gains Momentum—Time for a Market Shift?</li></ul><p>Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.03. The company had revenue of $8.29 billion for the quarter, compared to the consensus estimate of $8.33 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.07%.  As a group, equities analysts expect that  Medtronic plc will post 5.46 EPS for the current fiscal year. </p><h2>Medtronic Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which will be paid on Friday, April 11th. Shareholders of record on Friday, March 28th will be given a dividend of $0.70 per share. The ex-dividend date is Friday, March 28th. This represents a $2.80 dividend on an annualized basis and a yield of 2.99%. Medtronic's dividend payout ratio  is currently 85.11%. </p><h2>Insider Buying and Selling at Medtronic</h2><ul><li>Intuitive Surgical Leads the Pack in Robotic Surgery Innovation</li></ul><p>In related news, EVP Brett A. Wall sold 12,437 shares of Medtronic stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $90.00, for a total transaction of $1,119,330.00. Following the completion of the sale, the executive vice president now owns 40,979 shares of the company's stock, valued at $3,688,110. The trade was a 23.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own  0.20% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities analysts have recently issued reports on the company. Wells Fargo &amp; Company dropped their price target on Medtronic from $106.00 to $98.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, November 20th. Citigroup raised shares of Medtronic from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their target price for the company from $92.00 to $107.00 in a research report on Tuesday, March 4th. Royal Bank of Canada  reaffirmed an &#34;outperform&#34; rating and issued a $105.00 price target on shares of Medtronic in a research report on Wednesday, February 19th. Truist Financial cut their price objective on shares of Medtronic from $93.00 to $89.00 and set a &#34;hold&#34; rating on the stock in a report on Wednesday, December 18th. Finally, Robert W. Baird upped their target price on Medtronic from $90.00 to $91.00 and gave the stock a &#34;neutral&#34; rating in a report on Wednesday, February 19th. One research analyst  has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one  has assigned  a strong buy rating to the company's stock. According to MarketBeat.com, Medtronic  has a consensus rating of &#34;Hold&#34; and a consensus target price of $96.07.</p><p><b>View Our Latest Stock Report on Medtronic</b></p><h2>Medtronic Company Profile</h2> (Free Report)<p>Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Medtronic</li><li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li><li>How to Protect Your Portfolio When Inflation Is Rising</li><li>What is a support level?</li><li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li><li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li><li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li></ul><p><strong>Want to see what other hedge funds are holding MDT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medtronic Right Now?</h2><p>Before you consider Medtronic, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p><p>While Medtronic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Riverbend Wealth Management LLC acquired a new stake in Medtronic plc (NYSE:MDT) during Q4, purchasing 2,955 shares valued at approximately $237,000. Other institutional investors also adjusted their positions in MDT. Medtronic reported Q4 earnings of $1.39 per share, exceeding estimates, with revenue of $8.29 billion. The company declared a quarterly dividend of $0.70 per share, payable on April 11. Analysts have varied ratings on Medtronic, with price targets ranging from $89 to $107.</p>

Riverbend Wealth Management LLC Acquires New Stake in Medtronic plc (NYSE:MDT)